Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant chemotherapy timing with tamoxifen or toremifene in hormone receptor-positive node-positive breast cancer
ACTRN12606000532505Phase 3Completed
- Sponsor
- International Breast Cancer Study Group
- Start
- Nov 1993
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tamoxifen, toremifene, doxorubicin, epirubicin and cyclophosphamide in breast cancer (6 arms), sponsored by International Breast Cancer Study Group. Primary endpoints: Overall survival, Disease-free survival and 1 more. Started Nov 1993; status: completed.
02
Drugs
tamoxifentoremifenedoxorubicinepirubicincyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12606000532505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000532505.